Arcutis appoints David Topper as CFO, replacing interim CFO John Smither

Arcutis Biotherapeutics, Inc.

David Topper named CFO effective April 10, 2024; John Smither steps down and resigns April 30.
Topper receives $515k base salary, 45% target bonus, and equity awards of 310k options, 110k RSUs, 60k PSUs.
Topper brings 40+ years experience; most recently CFO at Inmagene, ex-General Atlantic, J.P. Morgan, Morgan Stanley.
Smither served as interim CFO since August 2023; previously Arcutis' first CFO leading IPO.
Topper's severance agreement includes 12 months base plus bonus, COBRA, and full equity acceleration on qualifying termination.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David Topper

Chief Financial Officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2024-04-10
Successor: John Smither
Filed: April 10, 2024, 7:59 PM ET

On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.

Role change

John Smither

Chief Financial Officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2024-04-10
Successor: David Topper
Filed: April 10, 2024, 7:59 PM ET

In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.

Departed

John Smither

Chief Financial Officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2024-04-30
Successor: David Topper
Filed: April 10, 2024, 7:59 PM ET

In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

David Topper was appointed as Chief Financial Officer at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 10, 2024, Arcutis Biotherapeutics, Inc. (the “Company”) announced the appointment of David Topper as the Company’s Chief Financial Officer, effective as of April 10, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John Smither changed role as Chief Financial Officer at Arcutis Biotherapeutics, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John Smither resigned as Chief Financial Officer at Arcutis Biotherapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

In connection with the appointment of Mr. Topper, Mr. Smither will step down as Chief Financial Officer, effective as of April 10, 2024, and will resign from the Company, effective as of April 30, 2024.

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-24-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.